Category: Joint ventures/collaborations
-
Bristol-Myers Squibb, Biotech in Cancer Drug Discovery Deal
17 March 2014. Bristol-Myers Squibb, a pharmaceutical company in New York, and Five Prime Therapeutics in South San Francisco, California are collaborating in discovery of cancer immunotherapies. The deal can be worth as much as $350 million to Five Prime Therapeutics, in which Bristol-Myers Squibb will also get a 5 percent stake. Five Prime Therapeutics…
-
Blood Biomarker Measured in Hockey Player Concussions
14 March 2014. Researchers at Quanterix Corp. in Lexington, Massachusetts, and universities in Sweden, tested the company’s method for detecting and measuring tau protein as an indicator of concussion in the blood of professional hockey players. The team led by Pashtun Shahim at University of Gothenburg, with colleagues at Quanterix, Sahlgrenska University Hospital, and University College London published their findings…
-
Virtual Fish in Development for Environmental Toxin Testing
13 March 2014. Researchers at Plymouth University in the U.K. and the pharmaceutical company AstraZeneca are developing a technique to gauge potential toxic effects of chemicals in rivers and oceans using cells from fish configured into a testing device. The three-year, £600,000 ($998,000) project of biologist Awadhesh Jha with colleagues from Plymouth and AstraZeneca is funded by U.K. science…
-
Biotech Partnership to Develop Non-Ricin Castor Plants
12 March 2014. Precision BioSciences Inc. and Novo Synthetix, biotechnology companies in Durham, North Carolina, are collaborating on a new type of castor bean, without the ricin poison that makes the beans difficult to process and market. Financial and intellectual property aspects of the deal were not disclosed. Beans from castor plants (Ricinus communis) have the potential to…
-
University, Spin-Off Partner on Enviro Flying Robotic Device
6 March 2014. University of Nevada in Reno and NevadaNano, a spin-off company from the university, are developing an aerial robotic device for environmental sensing and reporting over a large area. The project is funded by a $150,000 Small Business Technology Transfer grant from the U.S. Army. The project combines the university’s expertise in autonomous…
-
Early Trial Shows Gene Editing Potential to Treat HIV/AIDS
6 March 2014. Researchers from University of Pennsylvania, Albert Einstein College of Medicine, and the biotechnology company Sangamo BioSciences showed the company’s gene-editing technology could engineer the immune cells of HIV-positive patients to resist infection and decrease their viral loads. Results of the early-stage clinical trial led by Penn immunologist Carl June will be presented…
-
Pharma Alliance Extends Cancer Antibodies to Eye Disorders
4 March 2014. Santen Pharmaceutical Co. in Osaka, Japan is licensing antibodies developed as a cancer therapy by Tracon Pharmaceuticals in San Diego as treatments for eye diseases. Tracon is expected to earn $10 million in an upfront payment from Santen, as well as undisclosed milestone payments and royalties. Tracon develops biologic therapies for cancer,…
-
Genocea, Harvard, Dana-Farber to Partner on Melanoma
3 March 2014. Genocea Biosciences, a biotechnology company in Cambridge, Massachusetts, with Harvard Medical School and Dana-Farber Cancer Research Institute, are testing the company’s vaccine discovery platform to help target therapies for melanoma, an aggressive form of skin cancer. The collaboration is funded by Ludwig Institute for Cancer Research, but financial aspects of the partnership…
-
Clinical Trial Testing New, Current Breast Cancer Drugs
27 February 2014. The global pharmaceutical company Eisai Inc. is starting a late-stage clinical trial of its drug eribulin mesylate to treat certain types of recurring or metastatic breast cancer, compared to the current chemotherapy drug paclitaxel. The trial is a joint project of Eisai’s U.S. subsidiary, in Woodcliff Lakes, New Jersey, and Academic and…
-
Zoetis Funding Cat Health Foundation Research Awards
26 February 2014. Zoetis Inc., an animal health company in Florham Park, New Jersey, is funding grants to researchers for studies into pain, joint health, and kidney disorders in cats. Grants totaling $100,000 will be made available through the Winn Feline Foundation, with a due date for proposals of 21 April 2014. The company says…